Figure 1.
Disposition of all participants. All women who completed FREEDOM (ie, completed their 3 y visit, did not discontinue IP, and did not miss more than one dose) were eligible to participate in the FREEDOM extension. a, Two women who discontinued denosumab also entered the extension in the long-term denosumab group.